The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

A new study of 60,000 people around the world is shedding light on the possible brain health benefits of popular weight-loss ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Could Ozempic Treat Migraines, Too? Small Study Finds Early ... Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia. Skip to content Gizmodo.

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health issues like dementia ...

Gabapentin is routinely used to treat nerve pain and restless leg syndrome, but it might be riskier to our brain health than ...

Ozempic may lower dementia and nicotine dependence risk in people with type 2 diabetes. A recent study shows fewer cognitive deficits and lower smoking rates compared with other diabetes drugs.

Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...